Five Questions with James (Jamie) Rosenzweig, MD

Share on: 
Jamie Rosenzweig, MD

Jamie Rosenzweig, MD recently joined RTI-HS as Senior Director of Clinical Consulting and our 13th physician on staff. In his role, Rosenzweig serves as an internal consultant for projects that require diabetes, endocrinology, or internal medicine expertise as well as a consultant for our clients who develop products to treat diseases in those areas. We recently sat down with Jamie and asked a few questions so you could get to know him better. Here are his remarks:
 
Q1. What attracted you to working at RTI-HS?
I have spent most of my career in clinical research and patient care in an academic setting; however, I noticed that I was particularly attracted to projects that have an impact on the development of new medications, devices, and methods of health care. RTI-HS has great expertise in these areas and offers me new opportunities to provide innovative answers to questions in a real-world setting.
 
Q2. What about your background will be particularly helpful to our clients?
I have a lot of experience with clinical trials, serving as a PI in 18 studies. I was very active in protocol development and execution, especially in several large multicenter trials. I have also worked as a consultant with pharmaceutical companies, healthcare provider groups, and insurers.  It has been important for me to view things from multiple perspectives--that of the client, the patient, and the provider. 
 
Q3. Safety and quality are the cornerstones of any pharmaceutical research program—clinical or commercial. What do you bring to RTI-HS that will help ensure patient safety and research quality?
Patient safety has been a major focus for me. I served as Chair of the IRB and the Clinical Oversight Committee at the Joslin Diabetes Center, dealing with issues related to informed consent, patient rights, and physician responsibilities. I’m currently Co-Chair of the Endocrine Steering Committee of the National Quality Forum, which is responsible for nationwide adoption of guidelines in key clinical areas. I also chair the Quality Improvement Subcommittee of the Endocrine Society, which develops physician performance measures in the areas of diabetes and other metabolic and endocrine disease.
 
Q4. Given your long history working with medical associations and advocacy groups, including diabetes and endocrine organizations, where do you think the biggest opportunities are for those therapeutic areas?
I think we are at the cusp of some exciting new discoveries and developments. We should be seeing new closed-loop systems of glucose sensing and insulin delivery. Also, new medications and procedures to treat obesity and cardiovascular risk are under study, and key problems relating to stem cell treatment and immunology are being solved.
 
Q5. Professionally-speaking, what would you tell your younger self?
Jamie, don’t be afraid to take risks.  If you have a really good idea, pursue it.

Related Services: